BBIO News and Press, BridgeBio Pharma Inc. From 10/29/25

2025-10-29 10:22:37 ET from H.C. Wainwright issued a price target of $90.00 for BBIO on 2025-10-29 13:28:45. The adjusted price target was set to $90.00. At the time of the announcement, BBIO was trading at $65.7338. The overall price target consensus is at $72.25 with h...

2025-10-29 10:05:22 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Li...

2025-10-29 10:00:00 ET Major earnings expected after the bell on Wednesday include: Microsoft Corporation ( MSFT ) Alphabet ( GOOG ) Meta Platforms ( META ) Starbucks Corporation ( SBUX ) Teladoc Health ( TDOC ) Read the full article on Seek...

Amerigo Resources Ltd (ARREF) is expected to report $0.06 for Q3 2025 Bausch + Lomb Corporation (BLCO) is expected to report $0.16 for Q3 2025 Hayward Holdings Inc. (HAYW) is expected to report $0.11 for Q3 2025 Automatic Data Processing Inc. (ADP) is expected to report $2.44 for Q1 2...

PALO ALTO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced plans to release topline results of the autosomal dominant hy...

2025-10-28 10:15:19 ET H.C. Wainwright analyst issues BUY recommendation for BBIO on October 28, 2025 10:10AM ET. The previous analyst recommendation was Buy. BBIO was trading at $63.1788 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...

2025-10-27 13:09:28 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Li...

2025-10-27 11:17:51 ET BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 October 27, 2025 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO...

- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies - Primary interim analysis endpoint, glycosylated αDG, significantly increased by 1.8x change ...

PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host two separate bu...